fda warning letters glp-1 october 2025 news issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Compounded Semaglutide & Tirzepatide 2025:

Learn more: PharmaVoice Genetic Engineering & Biotechnology News Biotechnology #AI #Oncology #BiotechStocks #ClinicalTrials #LTRN To view or add a comment, sign in 65,534 followers

Whats it like? she says

This new study adds to a growing body of evidence that GLP-1 medicines may play a role in lowering dementia risk. After applying matching methods to control for confounding factors, the study included over 174,000 patients, evenly divided between the two treatment groups

Alhadeff et al., ad libitum fed rats compared with those effective in the VTA, indicating perhaps that NAc is somewhat less sensitive to the intake reducing effects of EX4 (Alhadeff et al., 2011)

Yet, patients and clinicians should consider this evidence when discussing potential risks and patients' values and preferences that might affect the risk/benefit balance